Acc Offers Guidance On Using Diabetes Drugs For Cv Event Reduction | Latest News RSS feed

Acc Offers Guidance On Using Diabetes Drugs For Cv Event Reduction - Latest News

ACC offers guidance on using diabetes drugs for CV event reduction

A new expert consensus document from the American College of Cardiology singled out liraglutide and empagliflozin as the preferred drugs in their classes to reduce cardiovascular risk among patients w... read more

AHA/ACC Issue New Cholesterol Management Guideline

published as a companion to the cholesterol guideline offers a more detailed explanation of the use of quantitative risk assessment in primary prevention for cardiovascular disease. The risk calculato... read more

Updated cholesterol guidelines offer more personalized risk assessment, additional treatment options for people at the highest risk

A special report simultaneously published as a companion to the cholesterol guidelines provides a more detailed perspective about the use of ... and offers cardiovascular accreditation to hospitals an... read more

Looking for another news?

Bristol-Myers Squibb (BMY) Q3 2018 Results - Earnings Call Transcript

I will say that CheckMate-511 I think offers some flexibility and optionality to doctors, and gives them some guidance, and Chris may want ... to be able to help us most understand how to use this dru... read more

Liraglutide significantly reduces risk for major cardiac events in elderly patients with diabetes

Liraglutide is among some of the newer treatments for diabetes and works through a glucagon-like peptide-1 agonist mechanism. This class of drugs has ... of adverse events in the older age group gener... read more

Eli Lilly Offers Healthy Outlook to Kick Off November

"Revenue growth driven by greater use ... Cardiovascular Events with a Weekly Incretin in Diabetes" (REWIND) study released on Monday showed superior efficacy for Trulicity, a key drug in Lilly's pipe... read more

High blood pressure redefined for first time in 14 years: 130 is the new high

The guidelines ... had a cardiovascular event such as a heart attack or stroke, or is at high risk of heart attack or stroke based on age, the presence of diabetes mellitus, chronic kidney disease or ... read more

Precision Medicine: Using Genomic Data to Predict Drug Side Effects and Benefits

In fact, the evidence suggests that such drugs might even offer ... reduction in major cardiac events experienced by people with diabetes who took Victoza® for up to five years. The new study outlines ... read more

Regeneron Pharmaceuticals (REGN) Q4 2017 Results - Earnings Call Transcript

There is a known potential risk of arterial thromboembolic events following the intravitreal use of VEGF inhibitors ... did not show any benefit in cardiovascular mortality. So how important do you th... read more

Janssen's first-in-class diabetes drug Invokana wins US approval

“Invokana provides patients with type 2 diabetes the option of a once-daily oral therapy that offers improved ... of diabetes drugs ever since GSK's Avandia was found to increase the risk of cardiovas... read more

Liraglutide shows cardiovascular benefit in routine practice

Liraglutide was associated with a 10 percent reduction in major cardiovascular events for patients with type 2 diabetes in a real-world population ... other second-line glucose-lowering drugs prescrib... read more

FeedsRSS Created by. Full RSS Feed | Privacy Policy | Contact Us